FDA Advises Against Antifungal Drug's Use In Studies
The recommendation comes nearly three months after the FDA unveiled extensive warnings about the treatment, which is known generically as ketoconazole. The agency said in July that even short-term use of the medication's oral form can lead to serious liver and kidney damage.
Ketoconazole belongs to a class...
To view the full article, register now.